

CARET Blood Specimen Summary. Number of participants with samples available by endpoint status, specimen type and timing of blood draw

Cancer type	N	<u>Pre-Randomization</u>		<u>Post-Randomization</u>		Whole Blood/DNA
		Serum	Plasma	Serum	Plasma	
Lung	1,445	1,411	421	1,148	182	971
Prostate	901	886	278	782	138	654
Breast (female)	432	430	120	352	43	294
Bladder	334	326	85	298	38	254
Colon	274	268	93	222	36	182
Head & Neck	186	178	51	143	26	126
Melanoma	165	161	47	142	20	130
Kidney	137	136	39	118	19	91
Lymphoma	128	123	35	109	15	84
Pancreas	105	102	27	82	13	50
Esophagus	101	99	26	80	14	61
Leukemia	84	84	20	68	8	52
Rectum	58	57	21	48	7	40
Brain	56	55	14	45	4	35
Mesothelioma	49	48	28	45	20	26
Liver	49	47	18	43	8	32
Multiple myeloma	45	44	17	37	7	29
Stomach	40	40	15	34	7	22
Ovary	36	35	10	29	2	25
Uterus	27	27	6	20	1	17
Gallbladder	20	19	4	16	4	11
Other cancers	289	280	66	230	25	184
Cancer free	13,920	13,610	3,053	11,235	1,145	10,016
All participants	18,314	17,913	4,316	14,835	1,701	12,976

Cause of death	N	<u>Pre-Randomization</u>		<u>Post-Randomization</u>		Whole Blood/DNA
		Serum	Plasma	Serum	Plasma	
Lung cancer	1,077	1,057	324	843	141	716
Other cancers	873	855	261	670	120	484
CVD, ASCHD	815	788	249	591	119	620
CVD, ASCVD	448	432	174	350	88	327
CVD, cerebrovascular	144	141	48	122	20	106
CVD, other	45	44	16	36	7	30
COPD	479	466	150	361	67	262
Other causes	831	810	250	643	120	484
Alive at end of f/u	13,602	13,320	2,844	11,219	1,019	9,947
All participants	18,314	17,913	4,316	14,835	1,701	12,976

- Participants are represented no more than once within each cancer type, but may be counted in more than one type.
- Serum collection at baseline, biennially during the intervention phase, and at the end of intervention.
- Whole blood collected at a single time in 1994-96 (whole blood is in spot cards and 2 ml vials).
- Aliquots of DNA extracted from whole blood are also available for lung and prostate cancer cases (and a matched set of controls) from whom whole blood was collected.